SER-252 (POZ-apomorphine)
Advanced Parkinson's Disease
Phase 1bActive - Registrational
Key Facts
Indication
Advanced Parkinson's Disease
Phase
Phase 1b
Status
Active - Registrational
Company
About Serina Therapeutics
Serina Therapeutics is advancing a proprietary polymer platform, POZylation, to 'turn good molecules into great medicines' by extending drug half-life, reducing dosing frequency, and improving patient convenience. The company's near-term value driver is SER-252, a long-acting formulation of apomorphine for advanced Parkinson's disease, which has entered a Phase 1b registrational trial under a 505(b)(2) pathway. Backed by decades of polymer research and strategic partnerships, Serina employs a capital-efficient development model focused on enhancing known molecules to address significant unmet needs in CNS and beyond.
View full company profileTherapeutic Areas
Other Advanced Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lecigon® (U.S. name not specified) | Intrance Medical Systems | Phase 3 |
| Lecigon | Lobsor Pharmaceuticals | Phase 3 |
| Infudopa IntraV | Dizlin Pharmaceuticals | Pre-clinical |